Three-minute EEG detects early Alzheimer’s signs in home tests, researchers say

Researchers at the University of Bath and the University of Bristol reported that a three-minute brainwave test called Fastball EEG can detect early signs of Alzheimer’s disease and mild cognitive impairment (MCI) when administered in patients’ homes.

The Fastball test records electrical activity in the brain while a person views a rapid series of images. Because it is a passive electroencephalogram (EEG) measure that does not require answers to questions or memory tasks, investigators say it is less likely to be affected by factors such as anxiety, education, culture or language than standard cognitive assessments. Study lead Dr. George Stothart, a cognitive neuroscientist in the Department of Psychology at the University of Bath, described the method as automatically capturing the brain’s responses to the visual stream.

In pilot testing carried out in participants’ homes, the researchers found that Fastball produced measurable signals linked to neural processing differences associated with MCI and early Alzheimer’s. The team reported the test could identify changes years before a clinical diagnosis, offering a potentially rapid screening tool that can be deployed outside clinical settings.

EEG measures electrical activity from the scalp that reflects brain responses to stimuli. Fastball uses a rapid visual presentation designed to elicit distinctive rhythmic brain responses; these can be detected and quantified in the frequency domain. Because the participant does not have to follow instructions or recall information, proponents say the test may reduce variability introduced by education level, language barriers or test anxiety that can confound traditional cognitive screening.

Researchers emphasized that the findings come from early-stage testing and that further validation in larger, diverse cohorts is required before Fastball can be recommended for routine clinical use. They said larger studies will be needed to define sensitivity and specificity across different stages of cognitive decline, to compare Fastball directly with established biomarkers and cognitive exams, and to determine how best to integrate the test into diagnostic pathways.

Early detection of Alzheimer’s and MCI is a focus of research because interventions, clinical monitoring and enrollment in therapeutic trials are more effective when pathology is identified sooner. Current diagnostic approaches include cognitive testing, neurological exams, brain imaging and fluid biomarkers; each has trade-offs in cost, accessibility and the influence of nonbiological factors. A brief, passive EEG that can be used at home could broaden access to screening and help identify candidates for more detailed evaluation, researchers said.

The teams from Bath and Bristol reported administering the test in nonclinical settings to assess feasibility and signal quality in real-world conditions. Home-based testing could reduce the burden on clinics and allow repeated measures over time to monitor progression, they said, but standardization of equipment, signal processing and interpretation will be necessary for widespread deployment.

Experts not connected to the study cautioned that preliminary positive findings require independent replication and head-to-head comparisons with established diagnostic tools. They also noted that any screening tool must be paired with clear pathways for follow-up, counseling and confirmatory testing to avoid false reassurance or unnecessary alarm.

The researchers plan further trials to refine the Fastball protocol, expand sample sizes, and assess how early the test can reliably detect disease-related changes relative to clinical diagnosis. If validated, the team said Fastball could become a low-cost adjunct to existing assessments for early identification of Alzheimer’s-related cognitive decline.